Johnson & Johnson (JNJ) on Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J shares slid nearly 2% in afternoon trading on the stock market today, as the medical giant does not expect the growth rate to continue. J&J’s earnings, excluding one-time items, rose 12% over the year-earlier quarter to $1.66 a share, beating analysts’ consensus by 11 cents. Sales rose 9% to
Medical giant Johnson & Johnson (JNJ) early Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J stock slid nearly 1.5% in morning trading, as the company does not expect the growth rate to continue. J&J’s earnings, excluding one-time items, rose 12% over the year-earlier quarter to $1.66 a share, beating analysts’ consensus by 11 cents. Sales rose 9% to $19.5 billion, about $500 million above estimates. The
Johnson & Johnson (JNJ) kicked off the medical industry’s Q1 earnings season with a modest upside surprise Tuesday, sending the stock up 1.5% in morning trading on the stock market today. J&J’s earnings, minus one-time items, totaled $1.54 a share, up 7% from the year-earlier quarter and beating analysts’ consensus by 6 cents. Sales rose 3.5% to $18.1 billion, about $100 million above estimates. The company also added a nickel to its 2014 EPS